v3.26.1
Basis of Presentation and Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Product Information [Line Items]        
Other operating expenses $ 10,000   $ 10,000  
Accounts receivable, net   $ 1,286,000   $ 2,254,000
Reserve for credit losses   974,000   1,014,000
Allowance for loans losses   7,478,000   7,478,000
Inventory, allowance for obsolescence   55,000   53,000
Goodwill   $ 1,769,000   1,769,000
Potential dilutive instruments issued and outstanding   0 0  
Cash   $ 4,100,000    
Working capital   39,900,000    
Sale of marketable securities   $ 2,800,000    
Impact BioMedical, Inc. [Member]        
Product Information [Line Items]        
Goodwill       $ 1,769,000
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk percentage   26.00% 25.00% 29.00%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk percentage   16.00% 18.00% 19.00%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk percentage   14.00% 15.00% 18.00%
Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk percentage   13.00% 11.00% 13.00%
Customer Four [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk percentage       12.00%
Customer Five [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]        
Product Information [Line Items]        
Concentration of credit risk percentage       11.00%